# The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)

> **NCT00832624** · PHASE4 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 10 (actual)

## Conditions studied

- Diabetes Mellitus Non-insulin-dependent

## Interventions

- **DRUG:** sitagliptin

## Key facts

- **NCT ID:** NCT00832624
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11-26
- **Primary completion:** 2009-09-02
- **Final completion:** 2009-09-02
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2017-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00832624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00832624, "The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00832624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*